title: Eradicating tumor drug resistance at its YAP-biomechanical roots.
abstract: Treatment with BRAF kinase inhibitors leads to rapid resistance and tumor regression in BRAF V600E mutant melanoma patients. However, the underlying mechanism of the developed tumor resistance is not fully clear. In this issue of The EMBO Journal, Kim and colleagues show that melanoma cells acquire resistance to BRAF inhibitors by changing cell shape, modifying their cytoskeleton and, in turn, activating the YAP/TAZ mechanotransduction pathway (Kim et al, 2016).
authors.affiliation: Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Zanconato
authors.affiliation: Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Piccolo
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008545:Melanoma / Q000378:metabolism*; D010750:Phosphoproteins / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000494:pharmacology*; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D007211:Indoles; D010750:Phosphoproteins; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D014157:Transcription Factors; D048493:Proto-Oncogene Proteins B-raf